EARLY TAVR – Ultra-Short Summary
EARLY TAVR – Ultra-Short Summary
Source:
Medical News (29 Oct 2025), based on EuroPCR 2025 analyses and TCT Late-Breaking Trial presentations ;
original EARLY TAVR publications in The New England Journal of Medicine (NEJM) and JACC: Cardiovascular Interventions (2024)
Keynotes:
1. Early TAVR is superior:
Reduced death/stroke/unplanned CV hospitalization (26.8% vs 45.3%).
(NEJM)
2. Fewer hospitalizations:
Unplanned CV admissions almost halved (20.9% vs 41.7%).
(NEJM)
3. Better quality of life:
Favorable outcomes at 2 years: 86.6% vs 68%.
(NEJM)
4. Waiting is unsafe:
Surveillance patients rapidly deteriorated:
25% needed TAVR at 6 months, 71% by 2 years.
(NEJM)
5. Delayed intervention increases cardiac damage & costs:
Emergency/urgent TAVR linked to worse outcomes and much higher Medicare costs.
(JACC Interventions)
Conclusion:
Early TAVR for severe asymptomatic AS prevents deterioration, improves outcomes, and is more cost-effective than “watchful waiting.”
